Business Description
Amneal Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US03168L1052
Share Class Description:
AMRX: Ordinary Shares - Class ATotal Employee Number:
8,500Compare
Compare
Traded in other countries / regions
AMRX.USA2DT.Germany Index Membership
Russell 2000Russell 3000 IPO Date
2018-05-07Description
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.07 | |||||
Equity-to-Asset | -0.01 | |||||
Debt-to-Equity | -59.38 | |||||
Debt-to-EBITDA | 4.31 | |||||
Interest Coverage | 1.87 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 2.35 | |||||
Beneish M-Score | -2.69 | |||||
WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -14.1 | |||||
3-Year EBITDA Growth Rate | 23.1 | |||||
3-Year EPS without NRI Growth Rate | 6.9 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 16.32 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 6.38 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 85.03 | |||||
9-Day RSI | 84.4 | |||||
14-Day RSI | 80.78 | |||||
3-1 Month Momentum % | 6.05 | |||||
6-1 Month Momentum % | -1.24 | |||||
12-1 Month Momentum % | 57.32 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.47 | |||||
Quick Ratio | 1.59 | |||||
Cash Ratio | 0.27 | |||||
Days Inventory | 120.06 | |||||
Days Sales Outstanding | 100.5 | |||||
Days Payable | 44.82 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -27.6 | |||||
Shareholder Yield % | -0.5 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 38.66 | |||||
Operating Margin % | 14.62 | |||||
Net Margin % | 4.01 | |||||
EBITDA Margin % | 20.55 | |||||
FCF Margin % | 6.18 | |||||
OCF Margin % | 10.04 | |||||
ROE % | Neg. Equity | |||||
ROA % | 3.47 | |||||
ROIC % | 16.62 | |||||
3-Year ROIIC % | -28.17 | |||||
ROC (Joel Greenblatt) % | 32.73 | |||||
ROCE % | 16.19 | |||||
Years of Profitability over Past 10-Year | 5 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 45.37 | |||||
Forward PE Ratio | 17.55 | |||||
PE Ratio without NRI | 20.16 | |||||
PS Ratio | 1.85 | |||||
Price-to-Free-Cash-Flow | 29.72 | |||||
Price-to-Operating-Cash-Flow | 18.32 | |||||
EV-to-EBIT | 19.07 | |||||
EV-to-Forward-EBIT | 7.6 | |||||
EV-to-EBITDA | 12.78 | |||||
EV-to-Forward-EBITDA | 6.63 | |||||
EV-to-Revenue | 2.63 | |||||
EV-to-Forward-Revenue | 1.64 | |||||
EV-to-FCF | 42.52 | |||||
Price-to-GF-Value | 2.28 | |||||
Price-to-Projected-FCF | 3.35 | |||||
Earnings Yield (Greenblatt) % | 5.24 | |||||
FCF Yield % | 3.42 | |||||
Forward Rate of Return (Yacktman) % | 1.04 |
Amneal Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Amneal Pharmaceuticals Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-10-30 08:30 | In 126 days | ||
| Third quarter earnings results for 2026 | 2026-10-30 | In 125 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-05 08:30 | In 40 days | ||
| Second quarter earnings results for 2026 | 2026-08-05 | In 39 days | ||
| Guidance call for 2026 | 2026-06-09 08:40 | 13.71 (-0.51%) | ||
| General meeting for 2026 | 2026-05-06 09:00 | 13.41 (+2.52%) | ||
| First quarter earnings conference call for 2026 | 2026-05-01 08:30 | 12.87 (+0.55%) | ||
| First quarter earnings results for 2026 | 2026-05-01 | 12.87 (+0.55%) | ||
| Barclays 28(th) Annual Global Healthcare Conference | 2026-03-10 11:00 | 13.25 (+0.23%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-02-27 08:30 | 14.49 (-0.62%) |
Show
Entries
Guru Commentaries on NAS:AMRX
No articles.
Press Release
Articles on Amneal Pharmaceuticals Inc
No articles.
Headlines
See More- 1
Jun 15, 2026
Top 3 Health Care Stocks That May Collapse This Quarter
Benzinga • 7:51am
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers